A clear strategy guides Dynamix in its mission to quickly discover and develop innovative drugs that benefit patients, physicians and its partners and increase shareholder value at the same time.
Dynamix uses its unique combination of INNNOVATION, SPEED, and capital EFFICENCY to create one of the best and most innovative small molecule drug pipelines for unmet medical needs in cancer and autoimmune disorders. We employ INNOVATION in every aspect of our drug discovery and development programs. We translate that innovative process into SPEED that significantly shortens development timelines. And we capitalize on that speed with capital and operations EFFICENCY, guided by our experienced, focused and dedicated management team.
Dynamix' broad pipeline and strong Drug Discovery Engine enable a two prong strategy:
- Dynamix will independently develop a few of its lead products all the way to advanced clinical trials, potentially partnering the programs after clinical proof of concept has been achieved.
- Dynamix will explore partnering the rest of its innovative pipeline earlier, at preclinical or early clinical stages, giving its partners timely access to its unique technology and gaining proceeds to support its advanced clinical programs.